NCT05144945View on ClinicalTrials.gov

Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea

PHASE3CompletedINTERVENTIONAL

Enrollment

301

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions

Influenza (Healthy Volunteers)

Interventions

BIOLOGICAL

Quadrivalent Recombinant Influenza Vaccine (RIV4)

Solution for intramuscular injection

BIOLOGICAL

Quadrivalent inactivated influenza vaccine (IIV4)

Suspension for intramuscular injection

Trial Locations (3)

15355

Investigational Site Number :4100003, Ansan-si

152-703

Investigational Site Number :4100001, Seoul

07441

Investigational Site Number :4100002, Seoul

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT05144945 - Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea | Biotech Hunter | Biotech Hunter